Our Bureau
Washington, DC
The Federal Government recently awarded Professor Venigalla B Rao with a multi-year, $5 million National Institute on Drug Abuse’s (NIDA) Avant-Garde Award Program for HIV and Substance Use Disorder Research grant. The term “avant-garde” is used to describe highly innovative approaches that have the potential to be transformative.
Venigalla B. Rao, Ph.D., is a Professor of Biology and the Founding Director of the Bacteriophage Medical Research Center at The Catholic University of America. He obtained a Ph.D. in biochemistry from the Indian Institute of Science and did postdoctoral research on bacteriophage T4 assembly and genome packaging at the University of Maryland School of Medicine.
The NIDA award supports innovative and creative scientists who propose high-impact research that will open new areas of HIV research and lead to potentially transformation avenues for the prevention and treatment of HIV among people who use drugs.
Rao’s gene therapy technology developed on the university campus could open the doors to healing and curing a variety of ailments and was spotlighted last year in the international scientific journal, Nature Communications.
“It’s a great honor for me and for the Catholic University of America to have received this award,” Rao said. Nearly 40 million people have HIV globally, and if Rao’s research on stem cells succeeds, he believes it could potentially lead to a cure for HIV and other genetic diseases.
“If we can repair the stem cells, then those repaired stem cells will repopulate the body,” Rao said. “The current HIV genetic disease will eventually be eliminated. The people don’t have to take any drugs, and they will be HIV resistant for future infections.”
Rao has received numerous research awards from the National Institutes of Health and the National Science Foundation and holds 24 U.S. and international patents. He is a Fellow of the American Academy of Microbiology and a Fellow of the National Academy of Inventors.
